The report "Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027", projected to reach USD 7.7 billion by 2027 from USD 5.0 billion in 2022, at a CAGR of 8.7% during the forecast period.
Browse 138 market data Tables and 46 Figures spread through 210 Pages and in-depth TOC on "Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cardiac-marker-market-64885447.html
Factors such as increasing incidence of cardiovascular diseases, increasing demand for early diagnois od cardiacovascular diseases, growing public-private investments to support for the clinical research of novel cardiac biomarkers, and risng geriatric patient population are anticiapted to fuel the growth of the market during the forecast period.
However, technical challenges related to the collection and storage of biomarkers, limited reimbursements, and regulatory changes are expected to restrain the market growth during the forecast period.
Based on products , kits and reagent segment accounted for the largest share of the cardiac marjer tetsing market in 2021.
On the basis of product , the cardiac marker testing market is segmented into kit & reagaents and Instruments. In 2021, the kit & reagaents segment accounted for the largest share of the cardiac marker testing market. Rising prevalence of cardiovascuoar diseases and increasing demand for rapid diagnosis of heart conditions have enhanced the usage of reagents and kits in diagnostic laboratories, academic institutes, and POC facilities. Moreover, rising volume of cardiac marker testing procedures and increase availability of different cardiac biomarker kits and reagents are contrinuting towards the largest share of the segment.
Based on biomarker type , Troponin I and T segment accounted for the largest share of the cardiac marker testing market in 2021.
Due to the high senitivity and specificity are marking troponin choice of biomarker among lab professionsl for the dection of cardiac injury. Moreover, the growing focus of players in introducing higher senistitvity troponin with capabililty of detection of lower level of concenttation of troponin in blood samples are expected to support the growth of the segment.
North America to command the largest share of the cardiac marker testing market in 2021
Based on region, the cardiac marker testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa North America accounted for the largest share of the cardiac marker testing market in 2021. The growth of the North American market is primarily driven by the increasing geriatric population, high incidence/prevalence of cardiovascular diseases, increasing number of cardiac marker testing procedures, and strong foothold of well-estanlished players with strong cardiac biomarker testing product portfolio. Moreover, the rising support from the government to support the discovery of new cardiac biomarker is likely to boost the cardiac marker testing market in North America.
Prominent players in the cardiac marker testing market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMérieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., Ltd. (China), Boditech Med Inc. (South Korea), Tulip Diagnostics (P) Ltd (India), BTNX Inc. (Canada), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), CTK Biotech, Inc. (US), Creative Diagnostics (US), LifeSign LLC. (US), CardioGenics Holdings Inc (Canada), and Atlas Medical GmbH (Germany).
Don’t miss out on business opportunities in Cardiac Marker Testing Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441